{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:34:13Z","timestamp":1791614053101,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Exploration of FVC as it relates to mortality in idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and ultimately fatal parenchymal lung disease, is important both clinically and to the current drug development paradigm. We evaluated the association between FVC decline and mortality in what is to our knowledge the largest well-characterized placebo cohort to date. Additionally, we sought to explore the risk of death caused by acute exacerbations and to further validate previously identified baseline predictors of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To validate and further characterize FVC decline, acute exacerbations, and previously identified baseline predictors as they relate to risk of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1,132 placebo subjects from six studies used for the clinical development of nintedanib and pirfenidone for the treatment of IPF were included in the present analysis. Deaths were captured as all-cause mortality. A stratified Cox proportional hazards model was used to test the association between baseline predictors, decline in FVC % predicted from baseline, acute exacerbations, and death. Decline in FVC % predicted and exacerbations were treated as time-varying covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subjects were followed for a mean of 60 weeks. At baseline, age, smoking status, lower FVC % predicted, and lower diffusing capacity of the lung for carbon monoxide % predicted were associated with an increased risk of death. The risk of death was also increased for subjects having one or more exacerbations with a hazard ratio (HR) of 10.3 (95% confidence interval [CI], 5.7\u201318.7). Compared with an FVC % predicted absolute decline from baseline at any time during the study of less than 5%, a decline greater than or equal to 10% to less than 15% was associated with an increased risk of death, with an HR of 2.2 (95% CI, 1.1\u20134.4), as was a decline greater than or equal to 15%, which was estimated with an HR of 6.1 (95% CI, 3.1\u201311.8). A decline ranging from greater than or equal to 5% to less than 10% was not associated with increased mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analyses validate the importance of baseline FVC, diffusing capacity of the lung for carbon monoxide, age, and smoking status as predictors of mortality and strengthen the association between decline in FVC and exacerbations with death, verifying a decline in FVC as an appropriate endpoint in IPF drug development.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT00514683, NCT01335464, NCT01335477, NCT00287729, NCT00287716, and NCT01366209).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201606-458oc","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T12:13:48Z","timestamp":1491567228000},"page":"1395-1402","source":"Crossref","is-referenced-by-count":165,"title":["Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-863X","authenticated-orcid":false,"given":"Miya O.","family":"Paterniti","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Bi","sequence":"additional","affiliation":[{"name":"Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinko","family":"Reki\u0107","sequence":"additional","affiliation":[{"name":"Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu A.","family":"Karimi-Shah","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrul A.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"2026020403002627400_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201306-1141WS","article-title":"Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report","volume":"189","author":"Blackwell","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib2","article-title":"Drugs@FDA: FDA approved drug products","author":"U.S. Food and Drug Administration (FDA)."},{"key":"2026020403002627400_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"Ley","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib4","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/09031936.00146314","article-title":"Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis","volume":"45","author":"Ley","year":"2015","journal-title":"Eur Respir J"},{"key":"2026020403002627400_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2213-2600(15)00093-4","article-title":"Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials","volume":"3","author":"Durheim","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026020403002627400_bib6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.2013.5827","article-title":"Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis","volume":"309","author":"Peljto","year":"2013","journal-title":"JAMA"},{"key":"2026020403002627400_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","article-title":"Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020403002627400_bib10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"2026020403002627400_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020403002627400_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","article-title":"Design of the INPULSIS\u2122 trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Richeldi","year":"2014","journal-title":"Respir Med"},{"key":"2026020403002627400_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026020403002627400_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2026020403002627400_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics"},{"key":"2026020403002627400_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","article-title":"Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1378\/chest.111.1.51","article-title":"Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome?","volume":"111","author":"Erbes","year":"1997","journal-title":"Chest"},{"key":"2026020403002627400_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.rmed.2007.11.008","article-title":"The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis","volume":"102","author":"Manali","year":"2008","journal-title":"Respir Med"},{"key":"2026020403002627400_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1378\/chest.06-1466","article-title":"Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Hamada","year":"2007","journal-title":"Chest"},{"key":"2026020403002627400_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/ajrccm.164.1.2007077","article-title":"Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation","volume":"164","author":"Mogulkoc","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2483071378","article-title":"Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study","volume":"249","author":"Shin","year":"2008","journal-title":"Radiology"},{"key":"2026020403002627400_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.108.2.305","article-title":"Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Hanson","year":"1995","journal-title":"Chest"},{"key":"2026020403002627400_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020403002627400_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"key":"2026020403002627400_bib29","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Martinez","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020403002627400_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020403002627400_bib31","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N Engl J Med"},{"key":"2026020403002627400_bib32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1183\/13993003.00419-2015","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm","volume":"46","author":"Ryerson","year":"2015","journal-title":"Eur Respir J"},{"key":"2026020403002627400_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"2026020403002627400_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1378\/chest.13-2424","article-title":"Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study","volume":"147","author":"Brown","year":"2015","journal-title":"Chest"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/9\/1395\/66715385\/annalsats_14_9_1395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/9\/1395\/66715385\/annalsats_14_9_1395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:00:37Z","timestamp":1770192037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/14\/9\/1395\/8453600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201606-458oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,9,1]]}}}